Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.76 |
| ▸ | MAOA | P21397 | 5/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.76 |
| ▸ | SDHA | P31040 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | CALML3 | P27482 | 1/20 | 0.76 |
| ▸ | F10 | P00742 | 6/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eperezolid SCHEMBL29421647 | 1.00 | MAOB (0.76) | MAOBMAOAPTGS1SDHALMNA | |
| Eperezolid SCHEMBL186562 | 1.00 | MAOB (0.76) | MAOBMAOAPTGS1SDHALMNA | |
| Eperezolid SCHEMBL5325217 | 0.99 | MAOB (0.75) | MAOBMAOAPTGS1SDHALMNA | |
| Eperezolid SCHEMBL5328753 | 0.96 | F10 (0.71) | MAOBMAOAPTGS1SDHALMNA | |
| Eperezolid SCHEMBL7497950 | 0.96 | MAOB (0.85) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6160239 | 0.94 | F10 (0.72) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6160243 | 0.94 | F10 (0.72) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL4163039 | 0.93 | MAOA (0.67) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL10151505 | 0.93 | MAOB (0.76) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL12674054 | 0.92 | MAOB (0.73) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635307-B1 | PHARMACEUTICAL COMPOSITIONS | MELINTA SUBSIDIARY CORP (US) | 2020-07-29 | — | — | EP | claimed |
| US-7892574-B2 | In situ applying oxazolidinone to ear, skins | PHARMACIA & UPJOHN COMPANY, LLC (US) | 2011-02-22 | — | — | US | claimed |
| EP-1096934-B1 | OXAZOLIDINONES TO TREAT EYE INFECTIONS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1301207-B1 | COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS, CONTAINING AN OXAZOLIDINONE COMPOUND, SULBACTAM AND AND AMPICILLIN | PHARMACIA & UPJOHN CO LLC (US) | 2005-08-10 | — | — | EP | claimed |
| EP-1304107-B1 | Use of oxazolidinines derivatives for treating psoriasis | PHARMACIA & UPJOHN CO LLC (US) | 2005-07-06 | — | — | EP | claimed |
| CN-1546030-A | Use of oxazolidinone derivatives for treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy | �������Ŷ���Լ��������˾ | 2004-11-17 | — | — | CN | claimed |
| US-6740652-B2 | Oxazolidinones to treat eye infections | PHARMACIA & UPJOHN COMPANY | 2004-05-25 | — | — | US | claimed |
| US-20040072841-A1 | Topical administration of oxazolidinones for transdermal delivery | FORD CHARLES W (US) | 2004-04-15 | — | — | US | claimed |
| EP-1019385-B1 | AMINOARYL OXAZOLIDINONE N-OXIDES | UPJOHN CO (US) | 2004-01-14 | — | — | EP | claimed |
| US-6613349-B2 | Administration of oxazolidinones for transdermal delivery | PHARMACIA & UPJOHN COMPANY | 2003-09-02 | — | — | US | claimed |
| US-20020022610-A1 | Compositions and methods for treating bacterial infections | PHARMACIA & UPJOHN COMPANY | 2002-02-21 | — | — | US | claimed |
| US-20020009483-A1 | TOPICAL ADMINISTRATION OF OXAZOLIDINONES FOR TRANSDERMAL DELIVERY | PHARMACIA & UPJOHN COMPANY | 2002-01-24 | — | — | US | claimed |
| WO-2002002095-A2 | COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS CONTAINING OXAZOLIDINONE COMPOUND, SULBACTAM AND AN AMPICILLIN | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-10 | — | — | WO | claimed |
| US-20010046992-A1 | Treatment of urinary tract infections with antibacterial oxazolidinones | BATTS DONALD HERMAN (US) | 2001-11-29 | — | — | US | claimed |
| CN-1305374-A | Oxazolidinones to treat eye infections | UPJOHN CO (US) | 2001-07-25 | — | — | CN | claimed |
| CN-1299281-A | Use of oxazolidinone derivatives for the treatment of psoriasis, arthritis and for reducing the toxicity of cancer chemotherapy | UPJOHN CO (US) | 2001-06-13 | — | — | CN | claimed |
| CN-1298302-A | Topical administration of oxazolidinones for transdermal delivery | UPJOHN CO (US) | 2001-06-06 | — | — | CN | claimed |
| EP-1032386-A1 | USE OF OXAZOLIDINONE DERIVATITIVES FOR TREATING PSORIASIS, ARTHRITIS AND REDUCING THE TOXICITY OF CANCER CHEMOTHERAPY | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-06 | — | — | EP | claimed |
| US-6040306-A | Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy | PHARMACIA & UPJOHN COMPANY | 2000-03-21 | — | — | US | claimed |
| WO-1999025344-A1 | USE OF OXAZOLIDINONE DERIVATIVES FOR TREATING PSORIASIS, ARTHRITIS AND REDUCING THE TOXICITY OF CANCER CHEMOTHERAPY | PHARMACIA & UPJOHN COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046992-A1 | Treatment of urinary tract infections with antibacterial oxazolidinones | UROD, OXA1L, PEPD | MAOB 888/4885MAOA 901/4885PTGS1 1410/4885 |
| US-20020022610-A1 | Compositions and methods for treating bacterial infections | BPGM, MGAM, OXA1L | MAOB 301/4885MAOA 1378/4885PTGS1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.